NO980473D0 - Anvendelse av flukonazol for å inhibere cancervekst - Google Patents

Anvendelse av flukonazol for å inhibere cancervekst

Info

Publication number
NO980473D0
NO980473D0 NO980473A NO980473A NO980473D0 NO 980473 D0 NO980473 D0 NO 980473D0 NO 980473 A NO980473 A NO 980473A NO 980473 A NO980473 A NO 980473A NO 980473 D0 NO980473 D0 NO 980473D0
Authority
NO
Norway
Prior art keywords
fluconazole
cancer growth
inhibit cancer
inhibit
growth
Prior art date
Application number
NO980473A
Other languages
English (en)
Other versions
NO980473L (no
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,180 external-priority patent/US5908855A/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO980473D0 publication Critical patent/NO980473D0/no
Publication of NO980473L publication Critical patent/NO980473L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO980473A 1995-08-04 1998-02-03 Anvendelse av flukonazol for å inhibere cancervekst NO980473L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US188995P 1995-08-04 1995-08-04
US08/674,180 US5908855A (en) 1996-07-16 1996-07-16 Compositions for treating viral infections
PCT/US1996/012474 WO1997005873A2 (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers

Publications (2)

Publication Number Publication Date
NO980473D0 true NO980473D0 (no) 1998-02-03
NO980473L NO980473L (no) 1998-04-03

Family

ID=26669622

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980473A NO980473L (no) 1995-08-04 1998-02-03 Anvendelse av flukonazol for å inhibere cancervekst

Country Status (18)

Country Link
EP (1) EP0841921A2 (no)
JP (1) JPH11510187A (no)
KR (1) KR19990036138A (no)
CN (1) CN1195288A (no)
AR (1) AR003175A1 (no)
AU (1) AU711966B2 (no)
BR (1) BR9609966A (no)
CA (1) CA2229024A1 (no)
CZ (1) CZ33798A3 (no)
HU (1) HUP9903420A3 (no)
IL (1) IL123095A0 (no)
MX (1) MX9800998A (no)
NO (1) NO980473L (no)
NZ (2) NZ503921A (no)
PL (1) PL324904A1 (no)
SK (1) SK14198A3 (no)
TR (2) TR199800270T1 (no)
WO (1) WO1997005873A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
FR2742405B1 (fr) * 1995-12-13 1998-02-27 Cgea Comp Gen Entre Auto Unite motrice susceptible d'etre accouplee a une enceinte roulante et vehicule resultant
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
WO2000027428A1 (en) * 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
EP1895012A1 (en) 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Method for inducing tumor apoptosis by increasing nitric oxide levels
US20120071539A1 (en) * 2006-12-12 2012-03-22 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
WO2019185521A1 (en) * 2018-03-26 2019-10-03 Westfälische Wilhelms-Universität Münster Ergosterol-biosynthesis inhibitor and influenza virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A3 (en) * 1985-03-29 1989-04-12 Pfizer Inc. Tioconazole and related compounds for prevention of sexually transmitted diseases and control of herpetic infections
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5665751A (en) * 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers

Also Published As

Publication number Publication date
HUP9903420A2 (hu) 2000-03-28
IL123095A0 (en) 1998-09-24
TR199800270T1 (xx) 1998-05-21
JPH11510187A (ja) 1999-09-07
SK14198A3 (en) 1999-03-12
NO980473L (no) 1998-04-03
BR9609966A (pt) 1999-02-02
CN1195288A (zh) 1998-10-07
PL324904A1 (en) 1998-06-22
MX9800998A (es) 1998-04-30
EP0841921A2 (en) 1998-05-20
AR003175A1 (es) 1998-07-08
CZ33798A3 (cs) 1998-06-17
TR199801739T2 (xx) 1998-12-21
NZ315184A (en) 2000-05-26
HUP9903420A3 (en) 2001-12-28
WO1997005873A3 (en) 1997-03-27
AU711966B2 (en) 1999-10-28
CA2229024A1 (en) 1997-02-20
AU6683396A (en) 1997-03-05
KR19990036138A (ko) 1999-05-25
NZ503921A (en) 2002-03-01
WO1997005873A2 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
NO980473D0 (no) Anvendelse av flukonazol for å inhibere cancervekst
NO980420D0 (no) Anvendelse av griseofulvin for å inhibere cancervekst
NO940083L (no) Kommunikasjonssystem over strömforsyningslinjer for å redusere effekten av signaloppheving
PL321590A1 (en) Compounds capable to cause liberation of the growth hormone
NO973009D0 (no) Fremgangsmåte for å inhibere kathepsin-k
NO943852D0 (no) Fremgangsmåte for å hemme bentap
DE69617652D1 (de) Verminderung des haarwuchses
NO980419D0 (no) Anvendelse av 1H,2,4-triazol derivater for å inhibere cancervekst
DE69613818T2 (de) Inhibierung von hydratbildung
NO975761D0 (no) Fremgangsmåte for å inhibere hydratdannelse
NO971895L (no) Inhibitorer av apolipoprotein <beta>-syntesen
NO975589L (no) Fremgangsmåte for å inhibere hydratdannelse
PL321680A1 (en) Derivatives of proline useful as inhibitors of human leucocytes elastase
NO996324L (no) Fremgangsmåte for fremstilling av mellomprodukter i syntese av benzopyranforbindelser
NO975581D0 (no) Fremgangsmåte for å redusere bentap
NO976024D0 (no) Anvendelse av N-cykloheksylbenzamider for å behandle tarmlidelser
NO940190L (no) Anvendelse av alpha-ketoglutarat
NO951122L (no) Anvendelse av hyaluronsyre for å forhindre arteriell restenose
DE69633529D1 (de) Bestimmung des Justierbits
NO982562D0 (no) Sammensetning for behandling av smerte
NO973609D0 (no) Fremgangsmåte for å inhibere effektene av IL-6
NO973963D0 (no) Fremgangsmåte for å hemme ovariecancer
MX9205491A (es) Sintesis regioselectiva de agentes anti-inflamatorios de 1,5-diaril pirazol
NO972613D0 (no) Anvendelse av additiver i kontrastmidler for å forbedre avbildning
NO980175D0 (no) Anvendelse av kationiske biopolymerer for å fremstille antiflassmidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application